{"id":47,"date":"2022-08-17T13:25:18","date_gmt":"2022-08-17T13:25:18","guid":{"rendered":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/?page_id=47"},"modified":"2026-03-31T06:55:21","modified_gmt":"2026-03-31T06:55:21","slug":"vimizim-dosing","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/vimizim-dosing\/","title":{"rendered":"Dosing"},"content":{"rendered":"<div id=\"acf-block-691ddbece7801\" class=\"page-header\">         \n            \n        <div class=\"header-image\" style=\"background-image: url(https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-content\/uploads\/sites\/2\/2022\/09\/Omar.png?v=0.46)\"><\/div>\n     \n    <div class=\"header-content\">\n                    <h1>VIMIZIM<sup>\u00ae<\/sup> (elosulfase alfa) should be administered once every week<sup>1<\/sup><\/h1>\n            <\/div>\n<\/div>\n\n<div id=\"acf-block-691ddbece7810\" class=\"block wrapped-content\">\n    <div class=\"wrapper\">\n        <div class=\"inner-wrapper\">\n                        <\/div>\n    <\/div>\n<\/div>\n\n<div id=\"acf-block-691ddbece8409\" class=\"block split-content equal-bias content-align-top bottom-border\" data-muted-autoplay=\"false\">\n\t<div class=\"wrapper\">\n\t\t<div class=\"inner-wrapper\">\n\t\t                                                                <div class=\"content-block first-block\">\n                                                                                                <ul>\n<li>\n<p class=\"p1\">VIMIZIM is an injectable solution for infusion that comes in 5-mL, single-use vials<sup>1<\/sup><\/p>\n<\/li>\n<li>\n<p class=\"p1\">The recommended dosage of VIMIZIM is 2 mg\/kg administered intravenously over a minimum range of 3.5 to 4.5 hours (based on infusion volume) once every week<sup>1<\/sup><\/p>\n<\/li>\n<li>Calculate the patient\u2019s dose of VIMIZIM as follows<sup>1<\/sup>:\n<ul>\n<li>\n<p class=\"p1\">Determine the number of VIMIZIM vials based on the patient\u2019s actual body weight in kg and the recommended dose<\/p>\n<\/li>\n<li>\n<p class=\"p1\">Select the appropriate size 0.9% Sodium Chloride Injection, USP infusion bag and calculate the infusion volume based on the patient\u2019s actual body weight:<\/p>\n<ul>\n<li>For patients who weigh less than 25 kg, the final infusion volume should be 100 mL<\/li>\n<li>For patients who weigh 25 kg or more, the final infusion volume should be 250 mL<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li>Before mixing VIMIZIM, ensure patient is able to undergo infusion and IV access is obtained<\/li>\n<\/ul>\n                                                                                    <\/div>\n                    \n                                            <div class=\"content-block second-block\">\n                                                                                                                                                                                                                                                                                    \n                                    \n                                                                                                                \n                                    \n                                    <figure>\n                                        <div class=\"image image-rounded\">\n                                                                                            <img decoding=\"async\" class=\"\" src=\"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-content\/uploads\/sites\/2\/2022\/09\/VIMIZIM-Bottle02.png?v=0.46\" alt=\"VIMIZIM Bottle\" \/>                                                                                    <\/div>\n                                                                            <\/figure>\n                                                                                    <\/div>\n                                                \t\t<\/div>\n\t<\/div>\n<\/div>\n\n<div id=\"acf-block-691ddbece843a\" class=\"block wrapped-content\">\n    <div class=\"wrapper\">\n        <div class=\"inner-wrapper\">\n                \n<figure id=\"acf-block-691ddbece8451\">\n    <div class=\"image image-rounded image-align-left\">\n                    <img decoding=\"async\" class=\"\" src=\"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-content\/uploads\/sites\/2\/2022\/08\/dosing-chart.png?v=0.46\" alt=\"\" \/>            <\/div>\n    <\/figure>\n        <\/div>\n    <\/div>\n<\/div>\n\n<div id=\"acf-block-691ddbece860c\" class=\"block wrapped-content\">\n    <div class=\"wrapper\">\n        <div class=\"inner-wrapper\">\n                \n<div id=\"acf-block-691ddbece8768\" class=\"block-wysiwyg\">\n            <p><strong>Important Administration Instructions<sup>1<\/sup><\/strong><\/p>\n<ul>\n<li>Administration of VIMIZIM should be supervised by a healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis<\/li>\n<li>Initiate VIMIZIM in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment<\/li>\n<li>This product must be diluted prior to administration and administered using a low-protein binding infusion set equipped with a low-protein binding 0.2 micrometer (\u03bcm) in-line filter<\/li>\n<li>Consider pre-medicating with antihistamines, with or without antipyretics, 30 to 60 minutes prior to the start of the infusion<\/li>\n<\/ul>\n<p><strong>Administration Modifications Due to Hypersensitivity Reaction<sup>1<\/sup><\/strong><\/p>\n<p>In the event of a severe hypersensitivity reaction (eg, anaphylaxis), discontinue the VIMIZIM infusion and immediately initiate appropriate medical treatment, including use of epinephrine. In the event of a mild to moderate hypersensitivity reaction, consider slowing or temporarily interrupting the infusion, or administering additional antihistamines, antipyretics, and\/or corticosteroids.<\/p>\n    <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\n<div id=\"acf-block-691ddbece878b\" class=\"block boxed-content top-border boxed-content-white\">\n\t<div class=\"wrapper\">\n\t\t<div class=\"inner-wrapper\">\n\t\t\t<div class=\"box\">\n\t\t\t\t\t\t\t\t\n<div id=\"acf-block-691ddbece8a7d\" class=\"image-text-block\">\n        <div class=\"content-block\">\n                                                    <p><a class=\"button button-text button-arrow\" href=\"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/getting-started-with-vimizim\/\" target=\"_self\">Find out how BioMarin helps support patients receiving VIMIZIM <\/a><\/p>\n                        <\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n<div id=\"acf-block-691ddbece8d0d\" class=\"block references\">\n    <div class=\"wrapper\">\n\t\t<div class=\"inner-wrapper\">\n\t\t    \t\t\t    <h4>Reference:\n<\/h4>\n\t\t\t\t\t\t                <ol>\n                                                                                                                        <li><span>VIMIZIM [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2025.\n<\/span><\/li>\n                                                            <\/ol>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-47","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VIMIZIM\u00ae (elosulfase alfa) Dosing<\/title>\n<meta name=\"description\" content=\"Dosing of Vimizim - guidelines for all patients and health care professionals.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/vimizim-dosing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VIMIZIM\u00ae (elosulfase alfa) Dosing\" \/>\n<meta property=\"og:description\" content=\"Dosing of Vimizim - guidelines for all patients and health care professionals.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/vimizim-dosing\/\" \/>\n<meta property=\"og:site_name\" content=\"BioMarin Vimizim HCP EN-US\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T06:55:21+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/vimizim-dosing\\\/\",\"url\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/vimizim-dosing\\\/\",\"name\":\"VIMIZIM\u00ae (elosulfase alfa) Dosing\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/#website\"},\"datePublished\":\"2022-08-17T13:25:18+00:00\",\"dateModified\":\"2026-03-31T06:55:21+00:00\",\"description\":\"Dosing of Vimizim - guidelines for all patients and health care professionals.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/vimizim-dosing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/vimizim-dosing\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/vimizim-dosing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dosing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/#website\",\"url\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/\",\"name\":\"BioMarin Vimizim HCP EN-US\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/hcp.biomarin.com\\\/en-us\\\/vimizim\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VIMIZIM\u00ae (elosulfase alfa) Dosing","description":"Dosing of Vimizim - guidelines for all patients and health care professionals.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/vimizim-dosing\/","og_locale":"en_US","og_type":"article","og_title":"VIMIZIM\u00ae (elosulfase alfa) Dosing","og_description":"Dosing of Vimizim - guidelines for all patients and health care professionals.","og_url":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/vimizim-dosing\/","og_site_name":"BioMarin Vimizim HCP EN-US","article_modified_time":"2026-03-31T06:55:21+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/vimizim-dosing\/","url":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/vimizim-dosing\/","name":"VIMIZIM\u00ae (elosulfase alfa) Dosing","isPartOf":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/#website"},"datePublished":"2022-08-17T13:25:18+00:00","dateModified":"2026-03-31T06:55:21+00:00","description":"Dosing of Vimizim - guidelines for all patients and health care professionals.","breadcrumb":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/vimizim-dosing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hcp.biomarin.com\/en-us\/vimizim\/vimizim-dosing\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/vimizim-dosing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/"},{"@type":"ListItem","position":2,"name":"Dosing"}]},{"@type":"WebSite","@id":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/#website","url":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/","name":"BioMarin Vimizim HCP EN-US","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages\/47","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/comments?post=47"}],"version-history":[{"count":86,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages\/47\/revisions"}],"predecessor-version":[{"id":3057,"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/pages\/47\/revisions\/3057"}],"wp:attachment":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/vimizim\/wp-json\/wp\/v2\/media?parent=47"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}